SynForU (TM) -HerCare probiotics show benefits in reducing vaginal yeast infections in pregnant women

0

KAOHSIUNG, Taiwan, August 31, 2021 / PRNewswire / – The first clinical study published in the Journal of Applied Microbiology documents that SynForU ™ -HerCare is effective in reducing vulvovaginal symptoms and the recurrence of vaginal candidiasis (VC) in pregnant women.

SynForU ™ -HerCare, Lactobacilli Strains, is designed to improve the quality of life of pregnant women with VC, one of the most common health problems affecting women worldwide. This probiotic mix isolated from dairy products, namely Lactobacillus plantarum LP115, Lactobacilli helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26 and Lactobacillus delbrueckii Undersp. lactis LDL114. Its quality, effectiveness and performance have been tested. It is superior in adherence too Hela Cell, hydrogen peroxide production and antibacterial activity compared to other intimate hygiene probiotics on the market.

“Most of the research on probiotics and vaginal Candidiasis in the first place Women in general emphasize without specifically targeting pregnant women. While VC can occur randomly in pregnant women; However, studies indicate that a higher prevalence was observed in pregnant women regardless of age, trimester, parity, occupation, and level of education. When it comes to VC treatment, studies suggest that probiotics are the preferred option over antifungal drugs, as these drugs are usually associated with side effects such as an increased rate of recurrence and drug resistance. Therefore, we developed further randomized studies to investigate the potential influence of probiotics on the prevention of VC, especially in pregnant women,says Dr. San Land Young, Human Healthcare Global Operations Head at SynbioTech.

Seventy-eight subjects 14-32 weeks gestation with VC completed the double-blind, placebo-controlled, randomized 8-week study. The intervention group took lactobacilli probiotics (two capsules / day with 9.5 log CFU / capsule) for 8 weeks.

The lactobacilli group showed a 45 percent reduction in vulvovaginal symptoms such as irritation, discharge, and burning sensation (P

The results suggest that the supplementation of SynForU ™ -HerCare vulvovaginal symptoms, recurrences of VC and. reduced improved emotional and social stress attributed to VC. In addition, SynForU ™ -HerCare demonstrated the potential benefit in reducing the risk of pregnancy-related constipation. Women can benefit from the convincing effects of SynForU ™ -HerCare, effective and scientifically supported probiotics. SynForU ™ -HerCare is now available worldwide.

Lisa Chen, Marketing Manager of SynbioTech commented,TThere are many probiotics with claims out there, but science is key. SynForU ™-HerCare is backed by solid science and it is our commitment to long-term care of women around the world, thereby Manufacturing a difference in their life“.

More information: https://www.synbiotech.com

Reference:
J Appl Microbiol. 2021 May 22. Doi: 10.1111 / jam.15158.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/synforutm-hercare-probiotics-shows-benefits-to-reduce-vaginal-yeast-infection-in-pregnant-women-301365765.html

SOURCE SYNBIO TECH INC


Source link

Share.

Comments are closed.